新型抗菌药物头孢地尔耐药现状及耐药机制研究进展  

Research progress on current situation and mechanisms of resistance of new antibiotic drug cefiderocol

作　　者：蔡淑梅 周曦 陈坤 牛会敏 江宇平 杨洁(综述) 张胜行(审校) CAI Shumei;ZHOU Xi;CHEN Kun;NIU Huiming;JIANG Yuping;YANG Jie;ZHANG Shenghang(Departmeent of Clinical Laboratory,Fuzong Clinical Medical School(900 Hospital),Fujian Medical University,Fuzhou,Fujian 350025,China;Department of Laboratory Medicine,Jintang Hospital,West China Hospital,Sichuan University/Jintang County First People′s Hospital,Chengdu,Sichuan 610400,China)

机构地区：[1]福建医科大学福总临床医学院(第九〇〇医院)检验科,福建福州350025 [2]四川大学华西医院金堂医院/金堂县第一人民医院实验医学科,四川成都610400

出　　处：《检验医学与临床》2025年第2期285-288,共4页Laboratory Medicine and Clinic

基　　金：福建省自然科学基金项目(2021J011275);福建省科技创新联合基金项目(2023Y9267);福建省科技创新平台项目(2021Y2017)。

摘　　要：头孢地尔是一种新型的儿茶酚-铁载体头孢菌素,具有治疗多种细菌感染的潜力,如铜绿假单胞菌、鲍曼不动杆菌、嗜麦芽窄食单胞菌感染等。尽管头孢地尔尚未在我国上市,但已经有文献报道了对头孢地尔的耐药菌株。该文综述了头孢地尔的特点及抗菌作用、临床常见细菌对头孢地尔的耐药情况、转铁蛋白基因突变及β-内酰胺酶、PBP突变等方面的耐药研究现状。然而国内关于头孢地尔耐药机制的研究报道相对较少,还需要做进一步的研究来更深入地了解头孢地尔的耐药机制。Cefiderocol is a novel catechol-iron carrier cephalosporin,which has the potential to treat a variety of bacterial infections,such as Pseudomonas aeruginosa,Acinetobacter baumannii and Stenotrophomonas maltophilia.Although the drug has not yet been marketed in China,there have been literature reports of drug-resistant strains of cefiderocol.This article reviews the characteristics and antimicrobial actions of cefiderocol,the resistance current situation of clinical common pathogens to it,transferrin gene mutations,β-lactamases and PBP mutations.However,there are relatively few reports in China on the resistance mechanisms of cefiderocol,so further research is needed to gain a deeper understanding of its resistance mechanisms.

关 键 词：头孢地尔 耐药 转铁蛋白 Β-内酰胺酶 PBP突变 

分 类 号：R978.1[医药卫生—药品]